Bristol Myers Squibb Acquires 2seventy bio for $5.00/share

Bristol Myers Squibb has agreed to acquire 2seventy bio at $5.00 per share, an 88% premium over its recent closing price. This strategic acquisition, valued at approximately $286 million, is recommended by 2seventy bio's Board of Directors.

Date: 11-03-2025

AI Rating: 7

Acquisition Details

Bristol Myers Squibb (BMY) is set to acquire 2seventy bio (TSVT) at a price of $5.00 per share. This acquisition signifies an 88% premium to 2seventy bio’s recent closing price of $2.66. The total equity value of the deal is around $286 million. From an investor’s perspective, such a premium typically signifies a strong interest in 2seventy bio from Bristol Myers Squibb, indicating expected future value or potential synergies from the acquisition.

2seventy bio's stock closed at $2.80, reflecting a 5.26% increase, further rising by 3.56% in after-hours trading, accentuating investor confidence regarding the acquisition. The favorable recommendation from 2seventy bio's Board of Directors to tender shares indicates a positive outlook and likely encourages other shareholders to follow suit.

Additionally, around 5.3% of the outstanding shares are under tender and support agreements, further solidifying the anticipated shareholder response to the price offer. This acquisition is projected to close in the second quarter of 2025, leading to the delisting of 2seventy bio’s common stock from Nasdaq, which is a critical factor for shareholders to consider.

Stocks: TSVT BMY